Incyte Corp., of Wilmington, Del., reported for the quarter ended June 30, 2018, GAAP net product revenues of JAK inhibitor Jakafi (ruxolitinib) were $346 million as compared to $276 million for the same period in 2017. For the six month period, product revenues of Jakafi were $659 million as compared to $527 million for the same period in 2017.